Samsung Biologics and Pfizer entered into a strategic partnership for the long-term commercial manufacturing of Pfizer’s multi-product portfolio. The companies entered into an initial manufacturing agreement in March 2023 for a Pfizer product. Under the new agreement, Samsung Biologics will provide additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio covering oncology, inflammation, and immunology. Samsung will use its newest facility, Plant 4, for the m...